TruScient® is licensed for the treatment of diaphyseal fractures as an adjunct to surgical standard of care (SOC) using open fracture reduction in dogs.
TruScient® consists of recombinant human bone morphogenetic protein-2 (rhBMP-2), applied to the fracture site in an absorbable collagen sponge (ACS). rhBMP-2 mimics the osteoinductive activity of natural BMPs to facilitate bone repair and remodelling.
How TruScient® works
During the natural bone healing process, BMPs induce a cascade of events leading to chrondrogenesis, osteogenesis, angiogenesis and synthesis of extracellular matrix.1
When TruScient® is applied to a fracture site, the ACS releases a steady flow of rhBMP-2. This amplifies the osteoinduction of mesenchymal stem cells (MSCs), inducing bone formation and accelerating the time to radiographic fracture union.
Download the TruScient® Summary of Product Characteristics for detailed technical information
- Lissenberg-Thunnissen SN et al. Int Orthop 2011;35:1271-1280.